(P 211) HEALTH-RELATED QUALITY OF LIFE IN IRISH SARCOMA PATIENTS

Objective: Health-related quality of life (HRQoL) is a multi-dimensional patient-reported outcome (PRO) crucial for comprehensive patient (pt) care. Monitoring PROs reduces symptom burden and hospitalisations and improves treatment (tx) adherence and survival. We aim to evaluate HRQoL using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in pts with sarcoma treated at Ireland’s national referral centre.

Methods: Pts ≥ 18 years with a diagnosis of bone or soft tissue sarcoma (STS) treated at St Vincent’s Hospital Group completed the EORTC QLQ-C30 questionnaire (version 3) between October 2024 and May 2025. Demographic and clinical data was collected. Responses were scored as per EORTC guidelines. Descriptive statistics were performed, and group comparisons were conducted using the Mann-Whitney U test and Spearman’s rank correlation.

Results: 101 pts were included for analysis with a median age of 56 [19-82]. The majority of pts were female (57%) with STS (82%), metastatic or unresectable disease (59%), and on active tx (61%). The median global health score (GHS) was 67. HRQoL domain scores were highest for emotional (83) and cognitive (83) functioning, followed by physical (73), role (67), and social (67). Pts with metastatic or unresectable disease reported significantly lower physical (p=0.002), role (p =0.002), and social functioning (p=0.0002). Female pts reported significantly lower emotional (p = 0.0045) and cognitive functioning (p = 0.032) compared with male pts. Pts on systemic tx reported lower social functioning than those not on tx (p < 0.0001). There were no significant differences in GHS or functional domains based on age, grouped histology (bone vs STS), or tumour location (extremity vs non-extremity).

Conclusion: Irish pts with sarcoma report an impaired HRQoL, with a mean GHS consistent with previously published data. Pts with metastatic or unresectable disease report significantly worse function across multiple domains, female pts report poorer emotional and cognitive function, and pts on active tx report more impaired social functioning. There were no clear disease-specific predictors of HRQoL, including across grouped histological subtypes or primary tumour location. Given the prognostic value of HRQoL and the relative paucity of real-world data in sarcoma, ongoing longitudinal assessment of this cohort will help characterise HRQoL across the disease continuum and guide strategies to improve pt care and outcomes.